Gary Nachman
Stock Analyst at Raymond James
(3.70)
# 798
Out of 4,944 analysts
94
Total ratings
59.15%
Success rate
4.6%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $3.39 | +489.97% | 2 | Aug 13, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $227 → $236 | $203.40 | +16.03% | 16 | Aug 1, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Outperform | $39 → $40 | $39.10 | +2.30% | 2 | Jul 31, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Strong Buy | $60 → $64 | $42.82 | +49.46% | 3 | Jul 31, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $18.79 | +49.02% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $436.18 | -31.68% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $2.50 | +700.00% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $25.07 | +47.59% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $14.00 | +35.71% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $290.13 | - | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $32.41 | -7.44% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $4.02 | +74.13% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $115.93 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $9.25 | -56.73% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $10.71 | +180.11% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $4.52 | +607.96% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $10.57 | +32.45% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $17.52 | -42.92% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $37.66 | -20.34% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.43 | +21,765.89% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $7.30 | +9.59% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $30.12 | -30.27% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $4.73 | +196.30% | 2 | Jun 14, 2018 |
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $3.39
Upside: +489.97%
AbbVie
Aug 1, 2025
Maintains: Outperform
Price Target: $227 → $236
Current: $203.40
Upside: +16.03%
LENZ Therapeutics
Jul 31, 2025
Maintains: Outperform
Price Target: $39 → $40
Current: $39.10
Upside: +2.30%
Ionis Pharmaceuticals
Jul 31, 2025
Maintains: Strong Buy
Price Target: $60 → $64
Current: $42.82
Upside: +49.46%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $18.79
Upside: +49.02%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $436.18
Upside: -31.68%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $2.50
Upside: +700.00%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $25.07
Upside: +47.59%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $14.00
Upside: +35.71%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $290.13
Upside: -
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $32.41
Upside: -7.44%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.02
Upside: +74.13%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $115.93
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $9.25
Upside: -56.73%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $10.71
Upside: +180.11%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $4.52
Upside: +607.96%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $10.57
Upside: +32.45%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $17.52
Upside: -42.92%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $37.66
Upside: -20.34%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.43
Upside: +21,765.89%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $7.30
Upside: +9.59%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $30.12
Upside: -30.27%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $4.73
Upside: +196.30%